Rising Prevalence Of Cardiovascular Disorders Drives Expansion Of Cardiac Biomarker Market Driver: Leading Transformation in the Cardiac Biomarkers Market in 2025

What combination of drivers is leading to accelerated growth in the cardiac biomarkers market?
The cardiac biomarker market is predicted to expand due to the increasing incidence of cardiovascular disorders. These are illnesses that impact the heart and blood vessels, including coronary artery disease, heart failure, and stroke. In response to certain heart conditions like myocardial infarction (heart attack), heart failure, and arrhythmias, cardiac biomarkers are released into the blood. These biomarkers can be detected via lab tests and their concentration can offer crucial diagnostic and prognostic data. For example, data from the British Heart Foundation, a UK-based cardiovascular research charity, in September 2024 showed about 7.6 million individuals in the UK suffer from heart and circulatory diseases. This includes nearly 4 million males and about 3.6 million females. These illnesses account for roughly 27% of all UK fatalities, resulting in over 170,000 deaths per year or roughly 480 deaths daily, which is equivalent to a death every three minutes. Therefore, the increasing incidence of cardiovascular disorders is responsible for propelling the cardiac biomarker market's growth.

Get Your Cardiac Biomarkers Market Report Here:
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

What is the projected compound annual growth rate (CAGR) of the cardiac biomarkers market from 2025 to 2034, and what factors influence it?
In recent times, the cardiac biomarkers market has witnessed swift expansion. The market is projected to increase from $18.99 billion in 2024 to $21.32 billion in 2025, representing a compound annual growth rate (CAGR) of 12.3%. The past years' growth can be credited to several factors such as growth in healthcare spending, backing by FDA approvals and regulatory bodies, an aging population, various awareness campaigns, high sensitivity troponin tests, and a rise in cardiovascular diseases.

In the upcoming years, the cardiac biomarkers market is anticipated to witness significant growth, expanding to $36.51 billion by 2029 with a compound annual growth rate (CAGR) of 14.4%. Factors contributing to this growth in the prediction period include an increase in chronic disease cases, an increased focus on early detection of diseases, developments in emerging markets, and a growing emphasis on biomarker panels due to an expanding senior population. The predicted trends during this period involve patient-focused healthcare approaches, applications of artificial intelligence and machine learning, integration of digital health, advances in technology for biomarker discovery, multi-marker panels, and the use of liquid biopsy in the field of cardiovascular medicine.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

How are the latest trends influencing the growth of the cardiac biomarkers market?
One key trend gaining traction in the cardiac biomarker market is the progression in technology. To maintain their market standing, companies in this sector are embracing innovative technologies. For example, in October 2023, Mindray, a medical devices firm based in China, introduced new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI) and NT-proBNP, to improve the diagnosis and treatment of cardiovascular diseases (CVDs). The hs-cTnI biomarker is crucial in detecting myocardial injury and its impressive detection rate and low imprecision make it invaluable for early screening and risk evaluation in situations like Acute Coronary Syndrome (ACS). On the other hand, NT-proBNP is a widely recognized marker for heart failure, aiding in its detection and management while showing high precision and minimal interference from common heart medications. Combined, these biomarkers considerably enhance clinical decision-making in critical cardiovascular care situations.

What are the major segments of the cardiac biomarkers market and their role in driving growth?
The cardiac biomarkers market covered in this report is segmented -

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics

Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels
2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels
6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

Which regions are key players in the growth of the cardiac biomarkers market?
North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the key firms paving the way for growth in the cardiac biomarkers market?
Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

What Is Covered In The Cardiac Biomarkers Global Market Report?

• Market Size Forecast: Examine the cardiac biomarkers market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the cardiac biomarkers market for a structured understanding.
• Key Players Overview: Analyze major players in the cardiac biomarkers market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the cardiac biomarkers market.
• Segment Contributions: Evaluate how different segments drive overall growth in the cardiac biomarkers market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the cardiac biomarkers market.
• Industry Challenges: Identify potential risks and obstacles affecting the cardiac biomarkers market.
• Competitive Landscape: Review strategic developments in the cardiac biomarkers market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.